In pediatric low-grade gliomas (PLGAs), sorafenib has paradoxically accelerated tumor growth regardless of BRAF or NF1 status, underscoring the complexity of these tumors.[33] In contrast, everolimus has shown promise as a well-tolerated alternative for radiographically progressive and recurrent pediatric low-grade gliomas (LGGs) when administered orally on a daily basis.[34] Selumetinib, another notable MEK inhibitor, has demonstrated efficacy in extending disease stability in children with progressive LGGs harboring BRAF or NF1 mutations.[35]. Here, MAP2K7 is linked to neoplasm.